About The Study: This decision analytic model showed that within the context of a high SARS-CoV-2 probability, monoclonal antibodies pre-exposure prophylaxis (mAbs PrEP) provision was cost-saving when provided to individuals at increased risk of severe COVID-19 if drug prices decrease to $275 and effectiveness is 75% or higher. When newer mAbs PrEP combinations become available, guidance on implementation should be formulated ensuring a fast rollout. Nevertheless, advocacy for mAbs PrEP use and critical discussion on drug prices are necessary to ensuring cost-effectiveness for different epidemic settings.

https://www.miragenews.com/monoclonal-covid-antibodies-health-outcomes-and-1042114/

#miragenews